On September 13, 2021 PharmaMar (MSE:PHM) reported that the World Health Organization (WHO) has confirmed the International Nonproprietary Name (INN) of its investigational anti-tumor compound PM14 as
ecubectedin (Press release, PharmaMar, SEP 13, 2021, View Source [SID1234596743]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The WHO has published a list of recommended INNs on its website, including this new name for PharmaMar’s active ingredient, which means that it can now be used officially.

Ectubectedin is currently in Phase I-II clinical development, both as a single agent and in combination with other drugs for the treatment of solid tumors. The fourongoing clinical trials with this compound are being conducted in 12 hospitals in Spain, France, the United Kingdom and the United States.

Ecubectedin is a compound that acts by specifically inhibiting RNA synthesis and active transcription of protein-coding genes.